BioCryst Pharmaceuticals | BCRX - Current Assets


BioCryst Pharmaceuticals reported $355.68M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
BioCryst Pharmaceuticals USD 355.68M 42.78M Sep/2025
Chugai Pharma JPY 1.74T 223.03B Dec/2025
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
DBV Technologies USD 88.88M 32.36M Sep/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Karyopharm Therapeutics USD 89.75M 8.12M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novavax USD 974.59M 55.08M Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025